August 25, 2022 — A new gallium-68 PET radiotracer appears effective for predicting higher risk of disease progression and mortality in patients with neuroendocrine tumors, according to a study published August 18 in the Journal of Nuclear Medicine.
Conclusion: Tumor lesion uptake of 68Ga-NODAGA-E[c(RGDyK)]2 was evident in patients with all grades of NEN. High uptake was associated with a poorer prognosis. Further studies are warranted to establish if 68Ga-NODAGA-E[c(RGDyK)]2 PET/CT may become a prediction tool for identification of patients eligible for treatments targeting integrin αvβ3.
In the simplest of terms, Ga68 Dotatate is targeting somatostatin receptors which are known to be expressed by most NETs, it can help indicate if treatment using somatostatin analogue therapy is feasible. Integrin αvβ3 recognizing cell surface integrins is upregulated on endothelial cells during angiogenesis and on tumor cells. Due to its involvement in tumor growth, invasiveness/metastases, and angiogenesis, integrin αvβ3 is an attractive target in cancers. It could therefore become a prediction tool for the identification of patients eligible for treatments targeting integrin αvβ3.
However, Ga68 Dotatate really only confirms that a NET may be present, particularly when uptake is intense. Ga68 NODAGA-E[c(RGDyK)]2 may be associated with prognosis when uptake is high, and this could influence therapeutic choices and approach.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors
Before you read thisThis information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might
Summary of July 2026 on RonnyAllan.NET July was similar to the other months of this year but views down on the previous two months due
I finally made 16 years since I was diagnosed on 26th July 2010. A milestone I was not certain at the time I would reach. However, as things progressed, as treatment was administered, and as I got used to living with Neuroendocrine Cancer, I eventually became more confident this was a possibility with the help […]
Intro Cushing’s syndrome is one of the most challenging hormonal complications seen in people with neuroendocrine neoplasms (NENs). It can be subtle, severe, or even
Today, 14th July 2026, I can confirm the 3 million views milestone has been reached. MASSIVE THANKS to you guys for reading and sharing.
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect
Disclaimer: This Spotlight provides general educational information about Iron. It is not a substitute for medical advice. Individual needs vary, particularly for those with conditions
Headline – half yearly point bonus edition Summary of June 2026 on RonnyAllan.NET June was similar to the other months of this year but slightly down on
Subscribe to get the latest posts sent to your email.
